Sign up to our newsletter Subscribe
NICE enough? Do NICE’s Decision Outcomes Impact International HTA Decision-making?

New medicines lead to improved patient outcomes and societal benefits, but R&D is a long and costly process. Ongoing health economics research aims to find the right balance between incentivising manufacturers to innovate and ensuring affordable access for health systems.